A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01326871 |
|
Recruitment Status : Unknown
Verified April 2016 by Altor BioScience.
Recruitment status was: Active, not recruiting
First Posted : March 31, 2011
Last Update Posted : April 13, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Transitional Cell Carcinoma of Bladder Urethra Cancer Ureter Cancer Malignant Tumor of Renal Pelvis | Drug: Cisplatin Drug: Gemcitabine Biological: ALT-801 | Phase 1 Phase 2 |
Bladder cancer is the fourth most common malignancy in men and the ninth most common in women in the US, with an estimated 68,810 new cases and 14,070 deaths for the year 2008. Approximately 90% to 95% of newly diagnosed patients are with transitional cell carcinomas (TCC). Approximately 20% to 25% contain advanced (muscle invasive or metastatic) disease. Muscle invasive bladder cancer is life threatening. Clinical trials have demonstrated that TCC is a chemotherapy-sensitive malignancy. Most current cancer treatment strategies involve the use of chemotherapeutic or biological drugs that have a low therapeutic ratio. The limitations are a consequence of effects of the therapeutic drug on normal tissues. One approach to control systemic exposure effects is to target the drug itself into the site of the tumor. For example, antibodies have been developed for use as tumor targeting agents and have had success in the clinic. However, despite the promise of antibody-based immunotherapy, there are limitations with these class of reagents. Even so, immunotherapy remains a promising approach to treat cancer.
One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. IL-2 has stimulatory effects on a number of immune cell types including T and B cells, monocytes, macrophages, lymphokine-activated killer cells (LAK) and natural killer (NK) cells. Based on the ability of IL-2 to provide durable curative anti-tumor responses, systemic administration of IL-2 has been approved to treat patients with metastatic melanoma or renal carcinoma. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is critical need for innovative strategies that enhance the effects of IL-2, to reduce its toxicity without compromising the clinical benefit, and to treat other diagnoses.
The study drug, ALT-801, is a biologic compound of interleukin-2 (IL-2) genetically fused to a humanized soluble T-cell receptor directed against the p53-derived peptides expressed on tumor cells. The p53 protein is one of the most important factors that protects from developing cancer and is also one of the most frequently mutated genes in many cancers, which include muscle-invasive bladder cancer. For any given cancer type, p53 dysfunction generally correlates with poor prognosis versus other the same site-of-origin. In some tumors, p53 mutation and over-expression also is associated with resistance to chemotherapy. This study is to further evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor sites that over-express p53 results in clinical benefits
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 90 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer |
| Study Start Date : | June 2011 |
| Estimated Primary Completion Date : | July 2017 |
| Estimated Study Completion Date : | October 2017 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II) |
Drug: Cisplatin
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given) Drug: Gemcitabine Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course Biological: ALT-801 Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Other Name: c264scTCR-IL2 |
| Experimental: ALT-801 and Gemcitabine (Phase II only) |
Drug: Gemcitabine
Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course Biological: ALT-801 Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Other Name: c264scTCR-IL2 |
- Maximum Tolerated Dose (MTD) and/or the recommended dose (RD) for dose expansion of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone [ Time Frame: 8 weeks ]
- Safety Profile [ Time Frame: 8 weeks ]Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment
- Clinical Benefit [ Time Frame: 12 weeks ]Number of participants with an objective response, which includes, a complete response,a partial response or a stable disease
- Progression Free Survival [ Time Frame: 36 months ]Number of participants with, 6-month, 9-month, 12-month, 18-month, 24-month, 30-month, or 36-month progression-free survival.
- Overall survival [ Time Frame: 36 months ]Number of participants with 6-month, 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival
- Pharmacokinetics and immunogenicity [ Time Frame: 9 weeks ]
Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801 for patients enrolled up to the stage 1 expansion.
Measures of anti-ALT-801 and IL-2 neutralizing antibodies
- Tumor Typing [ Time Frame: 1 month ]Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety and clinical benefits of study treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
ENTRY CRITERIA:
DISEASE CHARATERISTICS:
- Muscle invasive or metastatic urothelial cancer of bladder, ureters, renal pelvis, and urethra
-
Histologically or cytologically confirmed with a clinical plan that would potentially include cisplatin* plus gemcitabine systemic therapy or with disease refractory to a first-line platinum-based therapy (as defined in the protocol).
* Does not apply to patients screened for Phase II expansion
- Surgically incurable
PRIOR/CONCURRENT THERAPY:
- No concurrent radiotherapy, other chemotherapy, or other immunotherapy
- Must have recovered from side effects of prior treatments
- If prior Proleukin® treatment, must have had a clinical benefit
- No use of other investigational agents within 30 days of start or concurrently
PATIENT CHARACTERISTICS:
Age
- ≥ 18 years
Performance Status
- ECOG 0 or 1
Bone Marrow Reserve
- Absolute neutrophil count (AGC/ANC) ≥ 1,500/uL
- Platelets ≥ 100,000/uL
- Hemoglobin ≥ 10g/dL
Renal Function
-
Glomerular Filtration Rate (GFR):
- ≥ 50mL/min/1.73m^2 for cisplatin-containing regimen
- ≥ 40mL/min/1.73m^2 for non-cisplatin-containing regimen
Hepatic Function
- Total bilirubin ≤ 1.5 X ULN
- AST, ALT, ALP ≤ 2.5 X ULN, or ≤ 5.0 X ULN (if liver metastases exists)
- PT INR ≤ 1.5 X ULN
Cardiovascular
- No congestive heart failure < 6 months
- No unstable angina pectoris < 6 months
- No myocardial infarction < 6 months
- No history of ventricular arrhythmias
- No NYHA Class > II CHF
- Normal cardiac stress test required for subjects who are ≥ 50 years old, or have a history of EKG abnormalities, or have symptoms of cardiac ischemia or arrhythmia
- No uncontrolled hypertension
Pulmonary
- Not receiving chronic medication for asthma
- Normal clinical assessment of pulmonary function
Hematologic
- No evidence of bleeding diathesis or coagulopathy
Other
- Negative serum pregnancy test if female and of childbearing potential
- No women who are pregnant or nursing
- Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
- No known autoimmune disease other than corrected hypothyroidism
- No known prior organ allograft or allogeneic transplantation
- Not HIV positive
- No active systemic infection requiring parenteral antibiotic therapy
- No ongoing systemic steroid therapy required
- No history or evidence of CNS disease (Controlled brain metastases treated with radiation therapy or surgery where the disease has been clinically stable for a period of a least 3 months before screening is allowed)
- No psychiatric illness/social situation
- No other illness that in the opinion of the investigator would exclude the subject from participating in the study
- Must provide informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01326871
| United States, Arizona | |
| The University of Arizona Cancer Center | |
| Tucson, Arizona, United States, 85724 | |
| United States, Florida | |
| UF Health Center at Orlando Health | |
| Orlando, Florida, United States, 32806 | |
| Martin Health System | |
| Stuart, Florida, United States, 34994 | |
| H. Lee Moffitt Cancer Center and Research Institute | |
| Tampa, Florida, United States, 33612 | |
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Illinois | |
| Robert Lurie Comprehensive Cancer Center of Northwestern University | |
| Chicago, Illinois, United States, 60611 | |
| United States, Iowa | |
| University of Iowa Hospitals and Clinics | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Kansas | |
| University of Kansas Cancer Center | |
| Fairway, Kansas, United States, 66205 | |
| United States, Michigan | |
| Karmanos Cancer Center | |
| Detroit, Michigan, United States, 48201 | |
| United States, Minnesota | |
| University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
| United States, Missouri | |
| Washington University | |
| St. Louis, Missouri, United States, 63110 | |
| United States, North Carolina | |
| Levine Cancer Institute | |
| Charlotte, North Carolina, United States, 28203 | |
| United States, Oklahoma | |
| University of Oklahoma Health Science Center | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Pennsylvania | |
| St. Luke's Hospital and Health Network | |
| Easton, Pennsylvania, United States, 18045 | |
| Thomas Jefferson University Hospital | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| UPMC Cancer Center | |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Study Chair: | Hing C Wong, PhD | Altor BioScience |
| Responsible Party: | Altor BioScience |
| ClinicalTrials.gov Identifier: | NCT01326871 History of Changes |
| Other Study ID Numbers: |
CA-ALT-801-01-10 |
| First Posted: | March 31, 2011 Key Record Dates |
| Last Update Posted: | April 13, 2016 |
| Last Verified: | April 2016 |
Keywords provided by Altor BioScience:
|
cancer immunotherapy immunochemotherapy combinational therapy targeted metastatic muscle invasive interleukin-2 cisplatin gemcitabine antitumor TCR T-cell receptor |
p53 p53 gene p53 tumor supressor protein urothelial cancer bladder cancer renal pelvis cancer ureters cancer urethra cancer HLA-A2 positive HLA-A*0201/p53 aa264-272 HLA complex Muscle Invasive or Metastatic |
Additional relevant MeSH terms:
|
Carcinoma, Transitional Cell Neoplasms Ureteral Neoplasms Urinary Bladder Neoplasms Urethral Neoplasms Kidney Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Ureteral Diseases Urologic Diseases Urinary Bladder Diseases |
Urethral Diseases Kidney Diseases Gemcitabine Cisplatin Interleukin-2 Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |